GYRE
Gyre Therapeutics, Inc.
GYRE lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
GYRE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Strong |
GYRE's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are weak.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
GYRE PE Valuation
GYRE has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
GYRE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Stable | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect GYRE's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
HIMS has the edge over GYRE on the outlook, with more favorable revenue and profitability expectations.
GYRE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | $0.05 | +$2.86 |
| Q3 2024 | -$1.26 | +$19.44 |
| Q2 2024 | -$1.87 | +$20.63 |
| Q1 2024 | -$2.93 | -193% |
| Q4 2023 | -$2.81 | +$1.09 |
| Q3 2023 | -$20.70 | -463% |
| Q2 2023 | -$22.50 | -$18.60 |
| Q1 2023 | $3.15 | +$41.25 |
GYRE has the stronger earnings trend. Trailing diluted EPS is down 114% for GYRE versus HIMS down 257%.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
GYRE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $32.9M | +7.8% |
| Q2 2026 | $29.1M | +8.7% |
| Q1 2026 | $22.5M | +2.1% |
| Q4 2025 | $37.2M | +33% |
| Q3 2025 | $30.6M | +20% |
| Q2 2025 | $26.8M | +6.1% |
| Q1 2025 | $22.1M | -19% |
| Q1 2022 | $794K | -46% |
GYRE's revenue has grown year over year for six quarters in a row: $33M last quarter, up 7.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -4.6% | -27 points |
| Q2 2026 | -49% | -58 points |
| Q1 2026 | -42% | -52 points |
| Q4 2025 | 0.3% | -1.8 points |
| Q3 2025 | 23% | +6.1 points |
| Q2 2025 | 8.1% | -4.8 points |
| Q1 2025 | 10% | -19 points |
| Q4 2024 | 2.1% | N/A |
GYRE has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over GYRE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
GYRE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5M | -224% |
| Q2 2026 | -$17M | -1027% |
| Q1 2026 | $3M | +$3.3M |
| Q4 2025 | -$5.8M | -$3.1M |
| Q3 2025 | $4M | +288% |
| Q2 2025 | $1.8M | +$8.8M |
| Q1 2025 | -$251K | -109% |
| Q3 2024 | $1M | +$4.3M |
GYRE has burned cash in most quarters: −$25M over the past year, against $3M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over GYRE on cash generation, producing positive trailing cash flow while its opponent burns cash.
GYRE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.6% | +5.7M shares |
| 1 year | +2.2% | +2.3M shares |
| 3 years | +4955% | +104M shares |
| 5 years | +7124% | +105M shares |
GYRE has 106M diluted shares, up 2.2% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over GYRE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
GYRE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -15.1x | Net Cash |
| Q4 2025 | -2.7x | Net Cash |
| Q3 2025 | -2.8x | Net Cash |
| Q2 2025 | -3.2x | Net Cash |
| Q1 2025 | -1.3x | Net Cash |
| Q4 2024 | -0.7x | Net Cash |
| Q1 2023 | -1.3x | Net Cash |
| Q3 2022 | -2.0x | Net Cash |
GYRE has the edge over HIMS on leverage, with a lower net debt burden relative to earnings.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
GYRE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.1 | Neutral |
| Stochastic | 10.3 | Oversold |
GYRE's weekly RSI is 32 (neutral) and its Stochastic is 10 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
GYRE PE vs Healthcare Sector
| Metric | GYRE | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
GYRE has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
GYRE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.88 | 27% below |
| 20 week MA | $6.33 | 32% below |
| 50 week MA | $6.89 | 38% below |
| 100 week MA | $7.91 | 46% below |
| 200 week MA | $9.42 | 54% below |
GYRE is in a downtrend: it's below all five of its weekly moving averages, and 54% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
GYRE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $101.4 | $97.1 | -4.3% |
| 2021 | $97.1 | $15.9 | -84% |
| 2022 | $15.9 | $7.50 | -53% |
| 2023 | $7.50 | $25.7 | +243% |
| 2024 | $25.7 | $12.5 | -52% |
| 2025 | $12.5 | $7.26 | -42% |
| 2026 YTD | $7.26 | $4.30 | -41% |
GYRE has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.